Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Merck Continues to Thin Out
- Derek Lowe submits: As everyone knows, Merck MRK announced some big job cuts Wednesday – 7,200 positions, around 10% of the work force. It’s worth looking at the details of these, because they differ a bit from what’s been going on at some other companies. For one thing, the...
- External links 2008-10-23
- Wyeth Cuts Back Too: Are New Opportunities Being Created?
- Derek Lowe submits: So Wyeth WYE is cutting back on its therapeutic areas as well. According to that Bloomberg story, they're going to focus on oncology, inflammation, neuroscience, vaccines, metabolic diseases and muscular-skeletal disorders. That's still a pretty wide swath of territory, but note what it leaves out: cardiovascular...
- External links 2008-10-30
- Pension Fund Thinks Lilly / Imclone Deal Too Cheap
- Derek Lowe submits: I honestly didn’t think I’d ever get the chance to write about Imclone IMCL again. But never say never! It turns out that a pension fund, the State Retirement System of Massachusetts, is suing to block the Lilly LLY acquisition – because, hold on to your...
- External links 2008-10-31
- Not Running Out to Buy Shares in Pfizer
- Derek Lowe submits: I shouldn't pick on Jeff Kindler, because I wouldn't want to be CEO of Pfizer PFE, not the least little bit. But he gave an interview recently to the Financial Times, who asked him naturally about the Lipitor patent expiration. His answer: We're facing a...
- External links 2008-11-03
- AstraZeneca's Cardiovascular Drug: Risks Up, Risks Down
- Derek Lowe submits: AstraZeneca AZN took a pretty big risk in running a trial as big as the JUPITER one, but it seems to have paid off for them. As everyone has been reading, it appears that their Crestor rosuvastatin lowers the risk of cardiovascular events in patients with...
- External links 2008-11-10
- Did Novartis's Research Site Turn Out as Planned?
- Derek Lowe submits: I know that it’s not necessarily fair to drag out old press releases, but let’s do it anyway. Many readers will remember a few years back when Novartis NVS was making its big research move into Cambridge, renovating the old Necco candy building and hiring like...
- External links 2008-11-19
- Nitromed Is Archemix's Back Door onto the Stock Market
- Derek Lowe submits: Nitromed NTMD has been in trouble for several years now. They're a perfect example of a dog that caught a car: a company that was demolished by actually getting its drug on the market. No one wanted to pay for it, though, and after all that...
- External links 2008-11-21
- Trial Results Don't Look Good for GlaxoSmithKline's Diabetes Drug
- Derek Lowe submits: Avandia rosiglitazone has been under suspicion for the last couple of years, after data appeared suggesting a higher rate of cardiovascular problems with its use. GlaxoSmithKline GSK has been disputing this association all the way, as well they might, but today there’s yet more information to...
- External links 2008-11-25
- Will Merck's Atherosclerosis Drug Fare Better Than Pfizer's Did?
- Derek Lowe submits: Ever since the catastrophic failure of Pfizer's PFE HDL-raising CETP inhibitor torcetrapib in late 2006, everyone involved has wondered just what the problem was. There was a definitely higher cardiovascular-linked death rate in the drug-treatment group as opposed to placebo - which led to the screeching...
- External links 2008-12-02
- Roche Stalling for Time and Money in Genentech Deal
- Derek Lowe submits: Remember back earlier this year, when the temperatures were high, the Dow was at 11,000, and Roche (RHHBY.PK) announced that they wanted to buy the rest of Genentech DNA. So how’s that working out? Not all that well, as far as can be told...
- External links 2008-12-03
- Pfizer's Restructuring Still Leaves Employees in the Dark
- Derek Lowe submits: So, Pfizer PFE: it seems as if they’ve been going on about cutting their research staff for months now. Well, it has been months, and the whole thing is turning into a rather bitter joke for people in Groton, from what I can tell. This current...
- External links 2008-12-11
- Who Is the Worst Biotech CEO?
- Derek Lowe submits: I'm pleased to note that Adam Feuerstein over at TheStreet.com has announced his first-ever "Worst Biotech CEO" award. In what was surely a contested field, he's named Elan's ELN Kelly Martin as the winner. I was pulling for Ariad's ARIA Harvey Berger, who seems to have...
- External links 2008-12-14
- More Biotech Layoffs: Bristol-Myers Squibb, Entremed Feel the Pain
- Derek Lowe submits: I’m told by several people that Tuesday Bristol-Myers Squibb BMY is announcing layoffs in research and perhaps other areas. I don’t know how extensive these are, or how they’re spread across the New Jersey and Connecticut sites. What I do know is that accounting practices make...
- External links 2008-12-17
- Why I Pick on Pfizer
- Derek Lowe submits: I get occasional comments and e-mails asking why I’m so hard on Pfizer PFE. It’s not that I have anything personal against the company – I’ve never worked there, and they’ve never turned me down for a job. And I have a lot of friends there...
- External links 2009-01-07
- Perspective on Pfizer Layoffs
- Derek Lowe submits: Well, the researchers at Pfizer PFE have apparently been told that the latest round of layoffs are it, but I get the impression that this reassurance isn’t necessarily widely believed. People there and at other companies have been told that everything is rightsized and on track...
- External links 2009-01-18
- NitroMed Courted
- Derek Lowe submits: Remember that NitroMed NTMD/Archemix deal that I mentioned briefly back in November? Well, it's not going so smoothly. One of the largest NitroMed shareholders, Deerfield Management, objected to the whole idea, and proposed buying the company itself. Last week the company adjourned its shareholder meeting until...
- External links 2009-01-21
- Pfizer/Wyeth in Talks: No Surprise, But No Joy Either
- Derek Lowe submits: Well, as most of you will have heard, the news Friday morning was that Pfizer PFE has been in talks to buy Wyeth WYE for several months now. So they must be serious about it, eh? That's been one of the deals tossed around as a...
- External links 2009-01-25
- Will Pfizer Go About the Wyeth Deal Differently This Time?
- Derek Lowe submits: The Pfizer PFE/Wyeth WYE deal is on, and I would really, really prefer to write about something else this morning. The main thing we can hope for is that the company has decided, just possibly, that its previous takeovers didn’t quite work out the way that...
- External links 2009-01-27
- Pfizer / Wyeth Deal Will Be Costly No Matter What
- Derek Lowe submits: You might think that the Pfizer PFE/Wyeth WYE deal means that things are creeping back to normal in the M&A world. But the Wall Street Journal reports that Pfizer is having to pay about 8% for the money it's borrowing, and that the funds are due...
- External links 2009-01-28
- R&D Costs of the Pfizer / Wyeth Deal
- Derek Lowe submits: We’re seeing an example right now of one of the big costs of a drug company acquisition. While the Pfizer PFE/Wyeth WYE deal winds along, with all the regulatory and financial details being slowly worked out, what happens in the R&D organizations? Well, at Wyeth, I’d...
- External links 2009-01-30
- << Previous
- page 1 of 4
- Next >>
Refining Tags
- Pfizer Inc. (15 results)
- Merck & Co. Inc. (9 results)
- Wyeth (8 results)
- Eli Lilly & Co. (7 results)
- Genentech Inc. (6 results)
- Seeking Alpha (6 results)
- Healthcare (5 results)
- Novartis AG (3 results)
- Arena Pharmaceuticals Inc. (3 results)
- Human Resources (3 results)
- ARIAD Pharmaceuticals Inc. (3 results)
